肾上腺皮质癌孤儿药解腺瘤片的效果

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with poor prognosis. Adenomatase is currently the only drug approved for adrenocortical cancer. It is mainly used for inoperable, functional and non-functional adrenocortical cancer, adrenocortical hyperplasia and tumor-induced hypercortisolism. Today, let’s learn about the effects of the orphan drug Adenoma Tablets for adrenocortical cancer.

A clinical study showed that the total effective rate of mitotane combined with cisplatin reached 48.6%, the total tumor progression-free time was 9.1 months, and the overall survival time was 28.5 months. Among patients who were effective in this regimen, the tumor progression-free time reached 18.2 months, and the overall survival time was nearly 4 years. (47.7 months). Among them, 19.4% of patients had a progression-free time of more than 2 years, and nearly 10% of patients had a progression-free time of more than 5 years. 48.6% of patients had an overall survival time of more than 2 years, and 14% of patients had an overall survival time of more than 5 years. The treatment effect is significantly improved compared with other regimens.

Foreign studies have also found that Adenoma-Reducing Tablets can inhibit 5α-reductase and androgen activity, so active androgen replacement therapy can be carried out based on the patient's clinical manifestations and laboratory test results; Adenoma-Resolving Tablets can also increase the level of binding proteins in the blood, and thyroid hormone replacement therapy should be considered based on the free thyroxine level and the patient's clinical symptoms.

Adenoma tablets were approved by the U.S. Food and Drug Administration (FDA) in 1970 for the treatment of adrenocortical cancer. Subsequently, Adenoma Tablets were approved for marketing in Canada (1978), Brazil (1988), Hong Kong, China (1989), South Korea (2001) and other countries and regions, and was listed as an orphan drug by the European Medicines Agency (EMA) in 2002.

For children under the age of 18, the efficacy and safety of the adenoma tablets have not yet been fully determined. Doctors will determine the daily dose based on the patient's weight or body surface area. The daily dose for adults is 1 to 6 grams (taken in 3 to 4 times), and can be gradually increased to 8 to 10 grams per day. The generally recommended maximum daily dose is 18 grams.

If adverse reactions occur, reduce the dose until the maximum tolerated dose is determined. After the treatment of JieAdenoma Tablets is effective, it should be changed to 2~4g per day, with a course of treatment lasting 4~8 weeks. If taking the maximum tolerated dose is still ineffective for 3 months, stop treatment. If the patient can tolerate the higher dose, the dose should be continued to be increased until adverse effects occur.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.